LAP3 Antibody

What is LAP3 and what is its biological function?

LAP3 (Leucine aminopeptidase 3, also known as LAPEP, PEPS, or cytosol aminopeptidase) is a cytosolic metallopeptidase that catalyzes the removal of unsubstituted N-terminal hydrophobic amino acids from various peptides. The presence of Zn(2+) ions is essential for its peptidase activity, and its substrate specificity can be modulated by cofactors like Mn(2+), which enables specific Cys-Gly hydrolyzing activity. LAP3 plays significant roles in:

• Glutathione metabolism and degradation of glutathione S-conjugates

• Cell redox status regulation

• Protein degradation and peptide metabolism

• Cell cycle progression, particularly at the G1/S checkpoint

• Tumor cell proliferation, invasion, and angiogenesis

LAP3 belongs to the M17 aminopeptidase family and is found in various tissues and cultured cells, but notably not in red cells and skin .

What types of LAP3 antibodies are available for research?

Several types of LAP3 antibodies are available for research applications:

Each antibody type has specific advantages depending on the experimental conditions and target species .

What are the most reliable applications for LAP3 antibodies?

Based on validation data across multiple sources, LAP3 antibodies have demonstrated reliability in:

• Western blot (WB): Detecting the 56 kDa LAP3 protein in cell lysates

• Immunohistochemistry (IHC): Particularly in paraffin-embedded tissues

• Flow cytometry: For detection of intracellular LAP3

• Immunofluorescence (IF)/ICC: For cellular localization studies

Western blotting appears to be the most consistently validated application across different antibody sources, with most antibodies showing a clear band at the predicted 56 kDa size .

What are the optimal conditions for Western blot detection of LAP3?

For optimal Western blot detection of LAP3:

• Sample preparation: Use RIPA buffer with protease inhibitors (e.g., 1 mM PMSF) for cell lysis

• Protein loading: 10-20 μg of total protein per lane is typically sufficient

• Recommended dilutions:

  • Rabbit monoclonal antibodies: 1:1000 (e.g., ab154809)

  • Mouse monoclonal antibodies: 1:1000-1:6000 (e.g., 66417-1-Ig)

  • Polyclonal antibodies: 1:500-1:2000

• Predicted molecular weight: 56 kDa

• Secondary antibodies: Anti-rabbit or anti-mouse IgG conjugated to HRP, IRDye® 800CW, or IRDye® 680RD

• Blocking: 5% BSA in PBST is often effective

• Validated positive controls: HepG2, HeLa, and 293T cell lysates

For enhanced specificity, validated LAP3 knockout cell lines (e.g., Human LAP3 knockout A549 cell line ab266986) can serve as negative controls to confirm antibody specificity .

What are the recommended protocols for immunohistochemical detection of LAP3?

For effective IHC detection of LAP3:

• Tissue preparation: Paraffin-embedded sections are preferred

• Antigen retrieval: Heat-mediated antigen retrieval is essential before IHC staining

  • Use either TE buffer pH 9.0 or citrate buffer pH 6.0

• Antibody dilutions:

  • Rabbit monoclonal antibodies: 1:50 (e.g., ab154809)

  • Mouse monoclonal antibodies: 1:100-1:400 (e.g., 66417-1-Ig)

• Incubation: Overnight at 4°C for primary antibodies

• Detection system: HRP-conjugated secondary antibodies with DAB chromogen

• Validated tissues: Human kidney, lung, and ovarian carcinoma tissues have shown positive staining

• Localization pattern: Predominantly cytoplasmic staining

The choice of antigen retrieval buffer can significantly impact staining quality, with some antibodies performing better with specific buffer systems .

How can I optimize flow cytometry protocols for LAP3 detection?

For flow cytometric analysis of LAP3:

• Cell preparation: Permeabilization is essential as LAP3 is cytosolic

• Recommended fixation: 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100 or commercial permeabilization buffers

• Antibody dilution: Start with 1:10 for flow cytometry (e.g., ab154809)

• Controls:

  • Negative control: Isotype-matched antibody (e.g., negative rabbit IgG)

  • Positive control: 293T cells have shown reliable expression

• Detection: Use fluorophore-conjugated secondary antibodies

• Gating strategy: Exclude debris and doublets before analyzing LAP3 expression

Since LAP3 is an intracellular protein, effective permeabilization is critical for antibody access to the antigen.

How can I validate the specificity of LAP3 antibodies?

To validate LAP3 antibody specificity:

• Use positive and negative controls:

  • Validated positive cell lines: HepG2, HeLa, 293T

  • Negative controls: LAP3 knockout cell lines (e.g., Human LAP3 knockout A549 cell line)

• Conduct antibody validation experiments:

  • Western blot should show a single band at 56 kDa

  • Include loading controls (GAPDH, β-actin)

  • Compare results across multiple LAP3 antibodies

• Peptide competition assay: Pre-incubation with the immunizing peptide should abolish specific binding

• RNA interference: siRNA knockdown of LAP3 should reduce antibody signal

• Cross-validation with different techniques (e.g., IF results should match WB findings)

As demonstrated in the literature, antibody specificity issues can arise. The DNPEP study showed contradictory results between two antibodies (Abcam and Abgent), which was only resolved by creating CRISPR/Cas9 knockout models . This highlights the importance of rigorous validation approaches.

What are common pitfalls in LAP3 antibody experiments and how can they be avoided?

Common challenges with LAP3 antibody experiments include:

• Cross-reactivity with similar proteins:

  • Solution: Use knockout controls and validate with multiple detection methods

• High background in immunostaining:

  • Solution: Optimize blocking (5% BSA or normal serum), reduce antibody concentration, increase washing steps

• Weak or absent signal in Western blots:

  • Solution: Ensure proper antigen retrieval, optimize protein extraction methods, check for protease inhibitors in lysis buffers

• Contradictory results between antibodies:

  • Solution: Validate antibodies against knockout controls, verify epitope locations, use antibodies recognizing different regions of LAP3

• False positive detection:

  • Solution: Include isotype controls, perform peptide competition assays, validate across multiple experimental platforms

The case study of contradictory data obtained with two separate DNPEP antibodies illustrates how critical it is to validate antibody specificity with genetic knockout models .

What are the appropriate controls for LAP3 antibody experiments?

Proper controls for LAP3 antibody experiments include:

For definitive validation, genetic approaches (knockdown or knockout) remain the gold standard, as they can resolve contradictory antibody results, similar to the approach used in the DNPEP study .

How can LAP3 antibodies be utilized in cancer research?

LAP3 antibodies have proven valuable in cancer research through multiple applications:

• Prognostic biomarker studies:

  • LAP3 expression correlates with poor prognosis in hepatocellular carcinoma

  • IHC analysis shows LAP3 overexpression associates with lower differentiation, positive lymph node metastasis, and high Ki-67 expression

• Cell proliferation mechanisms:

  • LAP3 promotes HCC cell proliferation by regulating G1/S checkpoint

  • Western blot detection of cell cycle regulators (cyclin A, CDK2, CDK6) in conjunction with LAP3

• Drug resistance investigations:

  • LAP3 knockdown enhances sensitivity of HCC cells to cisplatin

  • Antibodies can monitor LAP3 expression changes during treatment response

• Metastasis studies:

  • LAP3 advances HCC cell migration

  • Detection of E-cadherin expression changes via Western blot with anti-E-cadherin antibodies

• Multi-parameter analysis:

  • Co-staining with proliferation markers (PCNA, Ki-67)

  • Combining with other biomarkers for comprehensive tumor profiling

Research has shown that LAP3 is significantly upregulated in HCC tissues and cell lines, with high expression correlating with aggressive clinical features and poor prognosis .

What role does LAP3 play in cellular transformation and how can antibodies help elucidate this process?

LAP3 has been implicated in cellular transformation, particularly in response to inflammatory stimuli:

• IFN-γ-induced transformation:

  • LAP3 contributes to IFN-γ-induced malignant transformation of breast microvascular endothelial cells (BMECs)

  • Transformation occurs through upregulation of HDAC2 expression

• Arginine metabolism:

  • LAP3 inhibits the expression of argininosuccinate synthetase (ASS1)

  • This leads to intracellular arginine depletion

  • Antibodies can track these protein expression changes

• Cell cycle regulation:

  • LAP3 promotes G1/S cell cycle transition through HDAC2-mediated mechanisms

  • Multi-parameter flow cytometry with LAP3 antibodies can assess cell cycle changes

• Inflammation response:

  • LAP3 expression is upregulated along with inflammatory cytokines following SARS-CoV-2 infection

  • This suggests a role in regulating inflammation

LAP3 antibodies enable researchers to monitor these processes through various detection methods, including ELISA to quantify intracellular and plasma LAP3 content during transformation events .

What are the latest experimental approaches for studying LAP3 interactions and signaling networks?

Advanced approaches for studying LAP3 interactions and signaling include:

• Data integration methodologies:

  • Combining chromatin IP-chip, subcellular localization, gene expression correlation, and deletion effects data

  • LAP3 has been identified in networks with contradictory data sources, suggesting complex regulatory mechanisms

• Protein-protein interaction studies:

  • LAP3 interactions can be studied using co-immunoprecipitation with LAP3 antibodies

  • Mass spectrometry identification of binding partners

  • Paralogy analysis and yeast two-hybrid assays provide complementary approaches

• Systems biology integration:

  • Combining transcriptomics, proteomics, and metabolomics data

  • Pointillist integration methods have been used to select or remove potential interactions

  • This approach showed 99.1% accuracy in identifying known protein-protein interactions

• Single-cell analysis:

  • LAP3 antibodies compatible with flow cytometry enable single-cell analysis

  • Correlation with other markers can reveal cell-specific functions

• CRISPR/Cas9 genetic manipulation:

  • Generation of LAP3 knockout cell lines and animal models

  • Essential for definitive validation of antibody specificity and LAP3 function

These approaches collectively enable researchers to place LAP3 within complex cellular networks and understand its diverse biological functions.

How do different antibody clones compare in their ability to detect LAP3 in various applications?

Different LAP3 antibody clones show varying performance across applications:

While monoclonal antibodies like EPR10330 offer high specificity with validated performance in knockout models, polyclonal antibodies may provide higher sensitivity but with potential cross-reactivity. The choice depends on the specific application and experimental needs .

What methodological considerations are important when studying LAP3 in different tissue and cell types?

When studying LAP3 across different tissues and cell types:

• Expression level variations:

  • LAP3 is expressed at varying levels across tissues

  • Adjust antibody concentrations accordingly (higher dilutions for high-expressing tissues)

  • Not expressed in red cells and skin, which can serve as negative controls

• Subcellular localization:

  • Predominantly cytoplasmic localization requires appropriate permeabilization

  • Different fixation methods may affect epitope accessibility

• Species considerations:

  • Verify antibody cross-reactivity for your species of interest

  • Some antibodies (e.g., 66417-1-Ig) react with human, mouse, rat, and pig samples

  • Others may have limited species reactivity

• Cell-type specific protocols:

  • Different cell types may require modified lysis buffers

  • For example, HCC tissues may benefit from specialized extraction protocols

• Context-dependent expression:

  • LAP3 expression changes with IFN-γ treatment, cancer progression, etc.

  • Include appropriate time points and controls

These considerations are crucial for obtaining reliable and reproducible results across different experimental systems.

What are the emerging research directions for LAP3 and how might antibody technology evolve to support them?

Emerging research directions for LAP3 and associated antibody technologies include:

• Therapeutic targeting:

  • LAP3 is being investigated as a potential therapeutic target for cancer treatment

  • Inhibitory antibodies or antibody-drug conjugates may be developed

  • Future antibodies may need to distinguish between active and inactive forms

• Biomarker development:

  • LAP3 as a prognostic biomarker in multiple cancers

  • Standardized IHC protocols with validated scoring systems

  • Multiplex antibody panels including LAP3 and other markers

• Single-cell analysis:

  • LAP3 antibodies compatible with CyTOF and single-cell proteomics

  • Higher sensitivity antibodies for detecting low abundance expressions

• Structural biology applications:

  • Antibodies that recognize specific conformational states

  • Tools to study LAP3's homododecamer tetrahedron structure

• In vivo imaging:

  • Development of LAP3 antibodies suitable for in vivo imaging

  • Fluorophore or radioisotope-conjugated antibodies for tracking LAP3 in animal models

• CRISPR screens and functional genomics:

  • Highly specific antibodies to validate CRISPR-based LAP3 modifications

  • Integration with large-scale functional genomics approaches

As LAP3's roles in cancer, inflammation, and cellular transformation become better understood, antibody technologies will likely evolve to provide more specific tools for targeting different functional aspects of this important enzyme.